ID: ALA5184527

Max Phase: Preclinical

Molecular Formula: C26H32F3N5OS

Molecular Weight: 519.64

Representations

Canonical SMILES:  Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C(F)(F)F)c1csc2ccccc12

Standard InChI:  InChI=1S/C26H32F3N5OS/c1-15(2)24-32-31-16(3)34(24)19-12-17-8-9-18(13-19)33(17)11-10-22(30-25(35)26(27,28)29)21-14-36-23-7-5-4-6-20(21)23/h4-7,14-15,17-19,22H,8-13H2,1-3H3,(H,30,35)/t17-,18+,19-,22-/m0/s1

Standard InChI Key:  CZADGVCEHBLIRV-WEMPKCCASA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 519.64

Molecular Weight (Monoisotopic): 519.2280

AlogP: 5.90

#Rotatable Bonds: 7

Polar Surface Area: 63.05

Molecular Species: BASE

HBA: 6

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 7.30

CX Basic pKa: 9.38

CX LogP: 2.74

CX LogD: 2.55

Aromatic Rings: 3

Heavy Atoms: 36

QED Weighted: 0.42

Np Likeness Score: -1.07

References

1. Xie X, Zheng YG, Chen H, Li J, Luo RH, Chen L, Zheng CB, Zhang S, Peng P, Ma D, Yang LM, Zheng YT, Liu H, Wang J..  (2022)  Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.,  65  (24.0): [PMID:36472561] [10.1021/acs.jmedchem.2c01383]

Source

Source(1):

• Scientific Literature